{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:27:05Z","timestamp":1793366825510,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-024-01898-y","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:03:04Z","timestamp":1730469784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["PIM1 kinase and its diverse substrate in solid tumors"],"prefix":"10.1186","volume":"22","author":[{"given":"Rituparna","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan Kumar","family":"Bahadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsa Pratibimbita","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragyanshree","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Pattanaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya R.","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Nikhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"1","key":"1898_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/med.21284","volume":"34","author":"M Narlik-Grassow","year":"2014","unstructured":"Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine\/threonine kinases in cancer. Med Res Rev. 2014;34(1):136\u201359. https:\/\/doi.org\/10.1002\/med.21284.","journal-title":"Med Res Rev"},{"issue":"4","key":"1898_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","volume":"37","author":"M Bachmann","year":"2005","unstructured":"Bachmann M, M\u00f6r\u00f6y T. The serine\/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37(4):726\u201330. https:\/\/doi.org\/10.1016\/j.biocel.2004.11.005.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"1898_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc2986","volume":"11","author":"MC Nawijn","year":"2011","unstructured":"Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11(1):23\u201334. https:\/\/doi.org\/10.1038\/nrc2986.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1898_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.4049\/jimmunol.168.2.744","volume":"168","author":"N Zhu","year":"2002","unstructured":"Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-\u03baB pathway. J Immunol. 2002;168(2):744\u201354. https:\/\/doi.org\/10.4049\/jimmunol.168.2.744.","journal-title":"J Immunol"},{"key":"1898_CR5","doi-asserted-by":"publisher","unstructured":"Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine\/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes & development. 2003;17(15):1841\u20131854. http:\/\/www.genesdev.org\/cgi\/doi\/https:\/\/doi.org\/10.1101\/gad.1105003.","DOI":"10.1101\/gad.1105003"},{"issue":"2","key":"1898_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ijc.20719","volume":"114","author":"C Fujii","year":"2005","unstructured":"Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, Mukaida N. Aberrant expression of serine\/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer. 2005;114(2):209\u201318. https:\/\/doi.org\/10.1002\/ijc.20719.","journal-title":"Int J Cancer"},{"issue":"7","key":"1898_CR7","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1074\/jbc.m409123200","volume":"280","author":"KC Qian","year":"2005","unstructured":"Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005;280(7):6130\u20137. https:\/\/doi.org\/10.1074\/jbc.m409123200.","journal-title":"J Biol Chem"},{"key":"1898_CR8","doi-asserted-by":"publisher","unstructured":"Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, et al. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PloS one. 2009;4(10):e7112. https:\/\/doi.org\/10.1371\/2Fjournal.pone.0007112","DOI":"10.1371\/2Fjournal.pone.0007112"},{"issue":"5","key":"1898_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bcp.2012.09.018","volume":"85","author":"C Blanco-Aparicio","year":"2013","unstructured":"Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013;85(5):629\u201343. https:\/\/doi.org\/10.1016\/j.bcp.2012.09.018.","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"1898_CR10","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.3390\/cancers14153565","volume":"14","author":"JR Julson","year":"2022","unstructured":"Julson JR, Marayati R, Beierle EA, Stafman LL. The role of PIM kinases in pediatric solid tumors. Cancers. 2022;14(15):3565. https:\/\/doi.org\/10.3390\/cancers14153565.","journal-title":"Cancers"},{"issue":"22","key":"1898_CR11","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1073\/pnas.86.22.8857","volume":"86","author":"R Amson","year":"1989","unstructured":"Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci. 1989;86(22):8857\u201361. https:\/\/doi.org\/10.1073\/pnas.86.22.8857.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1898_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1006\/bbrc.2001.4405","volume":"281","author":"K Mizuno","year":"2001","unstructured":"Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of pim-1 by hsp90. Biochem Biophys Res Commun. 2001;281(3):663\u20139. https:\/\/doi.org\/10.1006\/bbrc.2001.4405.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/1541-7786.MCR-04-0192","volume":"3","author":"K Petersen Shay","year":"2005","unstructured":"Petersen Shay K, Wang Z, Xing PX, McKenzie IF, Magnuson NS. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res. 2005;3(3):170\u201381. https:\/\/doi.org\/10.1158\/1541-7786.MCR-04-0192.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"1898_CR14","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1074\/jbc.M208246200","volume":"278","author":"JA Losman","year":"2003","unstructured":"Losman JA, Chen XP, Vuong BQ, Fay S, Rothman PB. Protein phosphatase 2A regulates the stability of Pim protein kinases. J Biol Chem. 2003;278(7):4800\u20135. https:\/\/doi.org\/10.1074\/jbc.M208246200.","journal-title":"J Biol Chem"},{"issue":"35","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/sj.onc.1210323","volume":"26","author":"J Ma","year":"2007","unstructured":"Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56\u03b2 subunit of PP2A. Oncogene. 2007;26(35):5145\u201353. https:\/\/doi.org\/10.1038\/sj.onc.1210323.","journal-title":"Oncogene"},{"issue":"4","key":"1898_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1111\/jcmm.13559","volume":"22","author":"YK Park","year":"2018","unstructured":"Park YK, Obiang-Obounou BW, Lee KB, Choi JS, Jang BC. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes. J Cell Mol Med. 2018;22(4):2488\u201397. https:\/\/doi.org\/10.1111\/jcmm.13559.","journal-title":"J Cell Mol Med"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-015-0477-z","volume":"14","author":"S Kreuz","year":"2015","unstructured":"Kreuz S, Holmes KB, Tooze RM, Lefevre PF. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015;14:1\u20134. https:\/\/doi.org\/10.1186\/s12943-015-0477-z.","journal-title":"Mol Cancer"},{"key":"1898_CR18","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood.V85.12.3494.bloodjournal85123494","volume":"85","author":"MT Yip-Schneider","year":"1995","unstructured":"Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. Blood. 1995;85:3494\u2013502. https:\/\/doi.org\/10.1182\/blood.V85.12.3494.bloodjournal85123494.","journal-title":"Blood"},{"issue":"6","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood.V93.6.1980.406k20_1980_1991","volume":"93","author":"S Matikainen","year":"1999","unstructured":"Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-\u03b1 Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R\u03b1, c-myc, and pim-1 Genes in Human T Cells. Blood, The Journal of the American Society of Hematology. 1999;93(6):1980\u201391. https:\/\/doi.org\/10.1182\/blood.V93.6.1980.406k20_1980_1991.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"5","key":"1898_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/MPA.0b013e31823cdd10","volume":"41","author":"KM Block","year":"2012","unstructured":"Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41(5):773\u20137781. https:\/\/doi.org\/10.1097\/MPA.0b013e31823cdd10.","journal-title":"Pancreas"},{"issue":"10","key":"1898_CR21","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2003-09-3126","volume":"103","author":"KJ Peltola","year":"2004","unstructured":"Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood. 2004;103(10):3744\u201350. https:\/\/doi.org\/10.1182\/blood-2003-09-3126.","journal-title":"Blood"},{"issue":"6","key":"1898_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","volume":"11","author":"T Shirogane","year":"1999","unstructured":"Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999;11(6):709\u201319. https:\/\/doi.org\/10.1016\/S1074-7613(00)80145-4.","journal-title":"Immunity"},{"key":"1898_CR23","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/onc.2008.123","volume":"35","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;35:4809\u201319. https:\/\/doi.org\/10.1038\/onc.2008.123.","journal-title":"Oncogene"},{"key":"1898_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.4213","volume":"11","author":"D Horiuchi","year":"2016","unstructured":"Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016;11:1321\u20139. https:\/\/doi.org\/10.1038\/nm.4213.","journal-title":"Nat Med"},{"key":"1898_CR25","doi-asserted-by":"publisher","unstructured":"Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14\u20133\u20133 binding and dissociation from Bcl-X L. BMC cell biology. 2006:1\u20134. https:\/\/doi.org\/10.1186\/1471-2121-7-1","DOI":"10.1186\/1471-2121-7-1"},{"key":"1898_CR26","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1038\/onc.2009.276","volume":"48","author":"JJ Gu","year":"2009","unstructured":"Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene. 2009;48:4261\u201371. https:\/\/doi.org\/10.1038\/onc.2009.276.","journal-title":"Oncogene"},{"issue":"11","key":"1898_CR27","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1182\/blood-2006-08-043356","volume":"109","author":"YL Hu","year":"2007","unstructured":"Hu YL, Passegu\u00e9 E, Fong S, Largman C, Lawrence HJ. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood, The Journal of the American Society of Hematology. 2007;109(11):4732\u20138. https:\/\/doi.org\/10.1182\/blood-2006-08-043356.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"1898_CR28","doi-asserted-by":"publisher","unstructured":"Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. haematologica. 2010;95(6):1004. https:\/\/doi.org\/10.3324\/haematol.2009.017079","DOI":"10.3324\/haematol.2009.017079"},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/cdd.2009.174","volume":"4","author":"K Nihira","year":"2010","unstructured":"Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, Yoshida K. Pim-1 controls NF-\u03baB signalling by stabilizing RelA\/p65. Cell Death Differ. 2010;4:689\u201398. https:\/\/doi.org\/10.1038\/cdd.2009.174.","journal-title":"Cell Death Differ"},{"key":"1898_CR30","doi-asserted-by":"publisher","unstructured":"Rout AK, Dehury B, Parida SN, Rout SS, Jena R, Kaushik N, et al. A review on structure-function mechanism and signaling pathway of serine\/threonine protein PIM kinases as a therapeutic target. International Journal of Biological Macromolecules. 2024:132030. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132030","DOI":"10.1016\/j.ijbiomac.2024.132030"},{"key":"1898_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117866","volume":"255","author":"NK Panchal","year":"2020","unstructured":"Panchal NK, Sabina EP. A serine\/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. Life Sci. 2020;255: 117866. https:\/\/doi.org\/10.1016\/j.lfs.2020.117866.","journal-title":"Life Sci"},{"key":"1898_CR32","doi-asserted-by":"publisher","unstructured":"Zhang X, Song M, Kundu JK, Lee MH, Liu ZZ. PIM kinase as an executional target in cancer. Journal of Cancer Prevention. 2018;23(3):109. https:\/\/doi.org\/10.15430\/JCP.2018.23.3.109","DOI":"10.15430\/JCP.2018.23.3.109"},{"issue":"1","key":"1898_CR33","first-page":"40","volume":"25","author":"XJ Liu","year":"2019","unstructured":"Liu XJ, Xiao QL, Wu X, Jin M, Shan T. Differential expression and clinical characteristics of Pim1 protein in different lesions of breast. Journal of Hainan Medical University. 2019;25(1):40\u20134.","journal-title":"Journal of Hainan Medical University"},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1111\/jcmm.15272","volume":"11","author":"H Liu","year":"2020","unstructured":"Liu H, Chen C, Ma D, Li Y, Yin Q, Li Q, et al. Inhibition of PIM1 attenuates the stem cell\u2013like traits of breast cancer cells by promoting RUNX3 nuclear retention. J Cell Mol Med. 2020;11:6308\u201323. https:\/\/doi.org\/10.1111\/jcmm.15272.","journal-title":"J Cell Mol Med"},{"key":"1898_CR35","doi-asserted-by":"publisher","unstructured":"Chen J, Tang G. PIM-1 kinase: a potential biomarker of triple-negative breast cancer. OncoTargets and therapy. 2019:6267\u201373. https:\/\/doi.org\/10.2147\/OTT.S212752","DOI":"10.2147\/OTT.S212752"},{"issue":"8","key":"1898_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-017-0998-y","volume":"34","author":"W Zhao","year":"2017","unstructured":"Zhao W, Qiu R, Li P, Yang J. PIM1: a promising target in patients with triple-negative breast cancer. Med Oncol. 2017;34(8):142. https:\/\/doi.org\/10.1007\/s12032-017-0998-y.","journal-title":"Med Oncol"},{"issue":"7","key":"1898_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12032-022-01675-2","volume":"39","author":"S Mahata","year":"2022","unstructured":"Mahata S, Sahoo PK, Pal R, Sarkar S, Mistry T, Ghosh S, et al. PIM1\/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer. Med Oncol. 2022;39(7):74. https:\/\/doi.org\/10.1007\/s12032-022-01675-2.","journal-title":"Med Oncol"},{"issue":"2","key":"1898_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bcp.2012.10.018","volume":"365","author":"M Malinen","year":"2013","unstructured":"Malinen M, J\u00e4\u00e4skel\u00e4inen T, Pelkonen M, Heikkinen S, V\u00e4is\u00e4nen S, Kosma VM, et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol Cell Endocrinol. 2013;365(2):270\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2012.10.018.","journal-title":"Mol Cell Endocrinol"},{"key":"1898_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-019-00966-3","volume":"26","author":"X Gao","year":"2019","unstructured":"Gao X, Liu X, Lu Y, Wang Y, Cao W, Liu X, et al. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. Breast Cancer. 2019;26:663\u201371. https:\/\/doi.org\/10.1007\/s12282-019-00966-3.","journal-title":"Breast Cancer"},{"key":"1898_CR40","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/nm.4198","volume":"11","author":"F Bras\u00f3-Maristany","year":"2016","unstructured":"Bras\u00f3-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;11:1303\u201313. https:\/\/doi.org\/10.1038\/nm.4198.","journal-title":"Nat Med"},{"issue":"7","key":"1898_CR41","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/modpathol.2012.244","volume":"26","author":"P Gazinska","year":"2013","unstructured":"Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol. 2013;26(7):955\u201366. https:\/\/doi.org\/10.1038\/modpathol.2012.244.","journal-title":"Mod Pathol"},{"key":"1898_CR42","doi-asserted-by":"publisher","unstructured":"Santio NM, Landor SK, Vahtera L, Yl\u00e4-Pelto J, Paloniemi E, Imanishi SY, et al. Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells. Oncotarget. 2016;7(28):43220. https:\/\/doi.org\/10.18632\/oncotarget.9215","DOI":"10.18632\/oncotarget.9215"},{"key":"1898_CR43","doi-asserted-by":"publisher","unstructured":"Landor SK, Santio NM, Eccleshall WB, Paramonov VM, Gagliani EK, Hall D, et al. PIM-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion. Journal of Biological Chemistry. 2021;296. https:\/\/doi.org\/10.1016\/j.jbc.2021.100593","DOI":"10.1016\/j.jbc.2021.100593"},{"issue":"34","key":"1898_CR44","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1038\/onc.2012.412","volume":"32","author":"S Ha","year":"2013","unstructured":"Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, et al. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene. 2013;32(34):3992\u20134000. https:\/\/doi.org\/10.1038\/onc.2012.412.","journal-title":"Oncogene"},{"issue":"27","key":"1898_CR45","doi-asserted-by":"publisher","first-page":"22959","DOI":"10.1074\/jbc.M111.338350","volume":"287","author":"DE Linn","year":"2012","unstructured":"Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, et al. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem. 2012;287(27):22959\u201368. https:\/\/doi.org\/10.1074\/jbc.M111.338350.","journal-title":"J Biol Chem"},{"issue":"1","key":"1898_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s42003-021-02723-9","volume":"4","author":"SE Ruff","year":"2021","unstructured":"Ruff SE, Vasilyev N, Nudler E, Logan SK, Garabedian MJ. PIM1 phosphorylation of the androgen receptor and 14\u20133-3 \u03b6 regulates gene transcription in prostate cancer. Communications Biology. 2021;4(1):1221. https:\/\/doi.org\/10.1038\/s42003-021-02723-9.","journal-title":"Communications Biology"},{"issue":"1","key":"1898_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s42003-020-01528-6","volume":"4","author":"RJ Ledet","year":"2021","unstructured":"Ledet RJ, Ruff SE, Wang Y, Nayak S, Schneider JA, Ueberheide B, et al. Identification of PIM1 substrates reveals a role for NDRG1 phosphorylation in prostate cancer cellular migration and invasion. Communications Biology. 2021;4(1):36. https:\/\/doi.org\/10.1038\/s42003-020-01528-6.","journal-title":"Communications Biology"},{"key":"1898_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-019-0463-y","volume":"17","author":"SK Eerola","year":"2019","unstructured":"Eerola SK, Santio NM, Rinne S, Kouvonen P, Corthals GL, Scaravilli M, et al. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion. Cell Communication and Signaling. 2019;17:1\u20136. https:\/\/doi.org\/10.1186\/s12964-019-0463-y.","journal-title":"Cell Communication and Signaling"},{"issue":"6","key":"1898_CR49","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202208136","volume":"222","author":"CC Jensen","year":"2023","unstructured":"Jensen CC, Clements AN, Liou H, Ball LE, Bethard JR, Langlais PR, et al. PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion. J Cell Biol. 2023;222(6): e202208136. https:\/\/doi.org\/10.1083\/jcb.202208136.","journal-title":"J Cell Biol"},{"key":"1898_CR50","doi-asserted-by":"publisher","unstructured":"Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, et al. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget. 2015;6(13):10880. https:\/\/doi.org\/10.18632\/oncotarget.3534","DOI":"10.18632\/oncotarget.3534"},{"issue":"1","key":"1898_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jcmgh.2022.09.014","volume":"15","author":"HH Chua","year":"2023","unstructured":"Chua HH, Chang MH, Chen YH, Tsuei DJ, Jeng YM, Lee PH, et al. PIM1-Induced Cytoplasmic Expression of RBMY Mediates Hepatocellular Carcinoma Metastasis. Cell Mol Gastroenterol Hepatol. 2023;15(1):121\u201352. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.09.014.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1898_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2018.12.015","volume":"444","author":"L Cao","year":"2019","unstructured":"Cao L, Wang F, Li S, Wang X, Huang D, Jiang R. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. Cancer Lett. 2019;444:116\u201326. https:\/\/doi.org\/10.1016\/j.canlet.2018.12.015.","journal-title":"Cancer Lett"},{"key":"1898_CR53","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.2147\/OTT.S180520","volume":"11","author":"Y Wu","year":"2018","unstructured":"Wu Y, Deng Y, Zhu J, Duan Y, Weng W, Wu X. Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer. Onco Targets Ther. 2018;11:6647\u201356. https:\/\/doi.org\/10.2147\/OTT.S180520.","journal-title":"Onco Targets Ther"},{"key":"1898_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107932","volume":"228","author":"M Adamaki","year":"2021","unstructured":"Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 2021;228: 107932. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107932.","journal-title":"Pharmacol Ther"},{"issue":"6849","key":"1898_CR55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/35090585","volume":"412","author":"SM Dhanasekaran","year":"2001","unstructured":"Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412(6849):822\u20136. https:\/\/doi.org\/10.1038\/35090585.","journal-title":"Nature"},{"key":"1898_CR56","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1038\/onc.2010.10","volume":"17","author":"J Wang","year":"2010","unstructured":"Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010;17:2477\u201387. https:\/\/doi.org\/10.1038\/onc.2010.10.","journal-title":"Oncogene"},{"issue":"14","key":"1898_CR57","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/onc.2011.371","volume":"31","author":"J Wang","year":"2012","unstructured":"Wang J, Anderson PD, Luo W, Gius D, Roh M, Abdulkadir SA. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene. 2012;31(14):1794\u2013803. https:\/\/doi.org\/10.1038\/onc.2011.371.","journal-title":"Oncogene"},{"issue":"4","key":"1898_CR58","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41391-020-0235-1","volume":"23","author":"MJ McAllister","year":"2020","unstructured":"McAllister MJ, McCall P, Dickson A, Underwood MA, Andersen D, Holmes E, et al. Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):596\u2013606. https:\/\/doi.org\/10.1038\/s41391-020-0235-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1898_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-020-00618-6","volume":"18","author":"NM Santio","year":"2020","unstructured":"Santio NM, Vainio V, Hoikkala T, Mung KL, L\u00e5ng M, Vahakoski R, et al. PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins. Cell Communication and Signaling. 2020;18:1\u20138. https:\/\/doi.org\/10.1186\/s12964-020-00618-6.","journal-title":"Cell Communication and Signaling"},{"issue":"34","key":"1898_CR60","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1371\/journal.pone.0026948","volume":"23","author":"DJ Tsuei","year":"2004","unstructured":"Tsuei DJ, Hsu HC, Lee PH, Jeng YM, Pu YS, Chen CN, et al. RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. Oncogene. 2004;23(34):5815\u201322. https:\/\/doi.org\/10.1371\/journal.pone.0026948.","journal-title":"Oncogene"},{"issue":"9","key":"1898_CR61","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.4161\/cbt.7.9.6418","volume":"7","author":"C Reiser-Erkan","year":"2008","unstructured":"Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008;7(9):1352\u20139. https:\/\/doi.org\/10.4161\/cbt.7.9.6418.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"1898_CR62","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/carcin\/bgr007","volume":"32","author":"D Xu","year":"2011","unstructured":"Xu D, Allsop SA, Witherspoon SM, Snider JL, Yeh JJ, Fiordalisi JJ, et al. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis. 2011;32(4):488\u201395. https:\/\/doi.org\/10.1093\/carcin\/bgr007.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1898_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2353\/ajpath.2009.080972","volume":"175","author":"J Chen","year":"2009","unstructured":"Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, et al. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am J Pathol. 2009;175(1):400\u201311. https:\/\/doi.org\/10.2353\/ajpath.2009.080972.","journal-title":"Am J Pathol"},{"key":"1898_CR64","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.4161\/rna.25274","volume":"10","author":"RA Burkhart","year":"2013","unstructured":"Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, et al. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. 2013;10:1312\u201323. https:\/\/doi.org\/10.4161\/rna.25274.","journal-title":"RNA Biol"},{"key":"1898_CR65","doi-asserted-by":"publisher","unstructured":"Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA et al. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res 2014; 74: 1128\u20131140 https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1915","DOI":"10.1158\/0008-5472.CAN-13-1915"},{"issue":"19","key":"1898_CR66","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1158\/0008-5472.CAN-13-1915","volume":"35","author":"FF Blanco","year":"2016","unstructured":"Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. 2016;35(19):2529\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1915.","journal-title":"Oncogene"},{"issue":"6","key":"1898_CR67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","volume":"3","author":"M Malumbres","year":"2003","unstructured":"Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459\u201365. https:\/\/doi.org\/10.1038\/nrc1097.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"1898_CR68","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1101\/gad.1549407","volume":"21","author":"B Ancrile","year":"2007","unstructured":"Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21(14):1714\u20139. https:\/\/doi.org\/10.1101\/gad.1549407.","journal-title":"Genes Dev"},{"issue":"5","key":"1898_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-3083.2006.01750.x","volume":"63","author":"J Scheller","year":"2006","unstructured":"Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63(5):321\u20139. https:\/\/doi.org\/10.1111\/j.1365-3083.2006.01750.x.","journal-title":"Scand J Immunol"},{"issue":"28","key":"1898_CR70","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/onc.2009.124","volume":"28","author":"J Chen","year":"2009","unstructured":"Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene. 2009;28(28):2581\u201392. https:\/\/doi.org\/10.1038\/onc.2009.124.","journal-title":"Oncogene"},{"key":"1898_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-016-0406-z","volume":"35","author":"J Xu","year":"2016","unstructured":"Xu J, Xiong G, Cao Z, Huang H, Wang T, You L, et al. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. J Exp Clin Cancer Res. 2016;35:1\u20132. https:\/\/doi.org\/10.1186\/s13046-016-0406-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1898_CR72","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3892\/or_00000050","volume":"20","author":"U Warnecke-Eberz","year":"2008","unstructured":"Warnecke-Eberz U, Bollschweiler E, Drebber U, Pohl A, Baldus SE, Hoelscher AH, et al. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases. Oncol Rep. 2008;20(3):619\u201324. https:\/\/doi.org\/10.3892\/or_00000050.","journal-title":"Oncol Rep"},{"issue":"10","key":"1898_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048575","volume":"7","author":"Y Jin","year":"2012","unstructured":"Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, Li JP. Overexpression of osteopontin, \u03b1v\u03b23 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS ONE. 2012;7(10): e48575. https:\/\/doi.org\/10.1371\/journal.pone.0048575.","journal-title":"PLoS ONE"},{"key":"1898_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-13-240","volume":"13","author":"W Pang","year":"2014","unstructured":"Pang W, Tian X, Bai F, Han R, Wang J, Shen H, et al. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer. 2014;13:1\u20135. https:\/\/doi.org\/10.1186\/1476-4598-13-240.","journal-title":"Mol Cancer"},{"issue":"3","key":"1898_CR75","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7150\/jca.13422","volume":"7","author":"R Jiang","year":"2016","unstructured":"Jiang R, Wang X, Jin Z, Li K. Association of nuclear PIM1 expression with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma and squamous cell carcinoma. J Cancer. 2016;7(3):324. https:\/\/doi.org\/10.7150\/jca.13422.","journal-title":"J Cancer"},{"key":"1898_CR76","doi-asserted-by":"publisher","unstructured":"Attili I, Bonanno L, Karachaliou N, Bracht JW, Berenguer J, Codony-Servat C, et al. SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research. 2020;9(5):1810. https:\/\/doi.org\/10.21037\/tlcr-20-681","DOI":"10.21037\/tlcr-20-681"},{"issue":"12","key":"1898_CR77","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nrm3013","volume":"11","author":"B Westermann","year":"2010","unstructured":"Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872\u201384. https:\/\/doi.org\/10.1038\/nrm3013.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"1898_CR78","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1038\/s41388-020-1168-9","volume":"39","author":"SS Chauhan","year":"2020","unstructured":"Chauhan SS, Toth RK, Jensen CC, Casillas AL, Kashatus DF, Warfel NA. PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer. Oncogene. 2020;39(12):2597\u2013611. https:\/\/doi.org\/10.1038\/s41388-020-1168-9.","journal-title":"Oncogene"},{"issue":"10","key":"1898_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076693","volume":"8","author":"YH Peng","year":"2013","unstructured":"Peng YH, Li JJ, Xie FW, Chen JF, Yu YH, Ouyang XN, et al. Expmunression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. PLoS ONE. 2013;8(10): e76693. https:\/\/doi.org\/10.1371\/journal.pone.0076693.","journal-title":"PLoS ONE"},{"issue":"2","key":"1898_CR80","first-page":"513","volume":"26","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhou Y, Liu S, Wang J, Ji R, Yan X. Prognostic and imomodulatory effects of PIM1 in colorectal carcinoma. Journal of BU ON: Official Journal of the Balkan Union of Oncology. 2021;26(2):513\u201320.","journal-title":"Journal of BU ON: Official Journal of the Balkan Union of Oncology"},{"key":"1898_CR81","doi-asserted-by":"publisher","unstructured":"Weirauch U, Beckmann N, Thomas M, Gr\u00fcnweller A, Huber K, Bracher F, et al. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia. 2013;15(7):783-IN28. https:\/\/doi.org\/10.1593\/neo.13172","DOI":"10.1593\/neo.13172"},{"issue":"5","key":"1898_CR82","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/cas.13562","volume":"109","author":"M Zhang","year":"2018","unstructured":"Zhang M, Liu T, Sun H, Weng W, Zhang Q, Liu C, et al. Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect. Can Sci. 2018;109(5):1468\u201379. https:\/\/doi.org\/10.1111\/cas.13562.","journal-title":"Can Sci"},{"issue":"24","key":"1898_CR83","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1038\/emboj.2011.413","volume":"30","author":"A Criollo","year":"2011","unstructured":"Criollo A, Niso-Santano M, Malik SA, Michaud M, Morselli E, Mari\u00f1o G, et al. Inhibition of autophagy by TAB2 and TAB3. EMBO J. 2011;30(24):4908\u201320. https:\/\/doi.org\/10.1038\/emboj.2011.413.","journal-title":"EMBO J"},{"issue":"24","key":"1898_CR84","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1016\/j.febslet.2015.11.001","volume":"589","author":"E Hu","year":"2015","unstructured":"Hu E, Ding L, Miao H, Liu F, Liu D, Dou H, et al. MiR-30a attenuates immunosuppressive functions of IL-1\u03b2-elicited mesenchymal stem cells via targeting TAB3. FEBS Lett. 2015;589(24):3899\u2013907. https:\/\/doi.org\/10.1016\/j.febslet.2015.11.001.","journal-title":"FEBS Lett"},{"key":"1898_CR85","doi-asserted-by":"publisher","unstructured":"Luo C, Yuan R, Chen L, Zhou W, Shen W, Qiu Y, et al. TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex. Oncotarget. 2017;8(63):106565. https:\/\/doi.org\/10.18632\/oncotarget.22497","DOI":"10.18632\/oncotarget.22497"},{"issue":"1","key":"1898_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111975","volume":"391","author":"Q Li","year":"2020","unstructured":"Li Q, Chen L, Luo C, Ge J, Zhu Z, Wang K, et al. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth. Exp Cell Res. 2020;391(1): 111975. https:\/\/doi.org\/10.1016\/j.yexcr.2020.111975.","journal-title":"Exp Cell Res"},{"issue":"1","key":"1898_CR87","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","volume":"137","author":"S Mabuchi","year":"2015","unstructured":"Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.003.","journal-title":"Gynecol Oncol"},{"key":"1898_CR88","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41388-020-1202-y","volume":"67","author":"RJ Rebello","year":"2018","unstructured":"Rebello RJ, Huglo AV, Furic L. PIM activity in tumours: A key node of therapy resistance. Advances in biological regulation. 2018;67:163\u20139. https:\/\/doi.org\/10.1038\/s41388-020-1202-y.","journal-title":"Advances in biological regulation"},{"key":"1898_CR89","doi-asserted-by":"publisher","unstructured":"Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, et al. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016;7(15):20152. https:\/\/doi.org\/10.18632\/oncotarget.7918","DOI":"10.18632\/oncotarget.7918"},{"issue":"1","key":"1898_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biom8010007","volume":"8","author":"AU Aziz","year":"2018","unstructured":"Aziz AU, Farid S, Qin K, Wang H, Liu B. PIM kinases and their relevance to the PI3K\/AKT\/mTOR pathway in the regulation of ovarian cancer. Biomolecules. 2018;8(1):7. https:\/\/doi.org\/10.3390\/biom8010007.","journal-title":"Biomolecules"},{"issue":"1","key":"1898_CR91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1749-6632.2011.06095.x","volume":"1229","author":"DH Suh","year":"2011","unstructured":"Suh DH, Kim MK, No JH, Chung HH, Song YS. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann N Y Acad Sci. 2011;1229(1):53\u201360. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06095.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1898_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","volume":"12","author":"JD Gordan","year":"2007","unstructured":"Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007;12(2):108\u201313. https:\/\/doi.org\/10.1016\/j.ccr.2007.07.006.","journal-title":"Cancer Cell"},{"key":"1898_CR93","doi-asserted-by":"publisher","unstructured":"Morais M, Dias F, Teixeira AL, Medeiros R. MicroRNAs and altered metabolism of clear cell renal cell carcinoma: Potential role as aerobic glycolysis biomarkers. Biochimica et Biophysica Acta (BBA)-General Subjects. 2017;1861(9):2175\u201385. https:\/\/doi.org\/10.1016\/j.bbagen.2017.05.028","DOI":"10.1016\/j.bbagen.2017.05.028"},{"issue":"8","key":"1898_CR94","first-page":"1599","volume":"6","author":"CM Labak","year":"2016","unstructured":"Labak CM, Wang PY, Arora R, Guda MR, Asuthkar S, Tsung AJ, et al. Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment. Am J Cancer Res. 2016;6(8):1599.","journal-title":"Am J Cancer Res"},{"issue":"11","key":"1898_CR95","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.7150\/jca.13422","volume":"29","author":"U Warnecke-Eberz","year":"2009","unstructured":"Warnecke-Eberz U, Bollschweiler E, Drebber U, Metzger R, Baldus SE, Hoelscher AH, et al. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 2009;29(11):4451\u20135. https:\/\/doi.org\/10.7150\/jca.13422.","journal-title":"Anticancer Res"},{"key":"1898_CR96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-011-0097-2","volume":"15","author":"B Yan","year":"2012","unstructured":"Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, et al. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer. 2012;15:188\u201397. https:\/\/doi.org\/10.1007\/s10120-011-0097-2.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1898_CR97","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.3892\/mmr.2015.4296","volume":"12","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhou X, Shan B, Han J, Wang F, Fan X, et al. Downregulation of microRNA-33a promotes cyclin-dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation. Mol Med Rep. 2015;12(5):6491\u2013500. https:\/\/doi.org\/10.3892\/mmr.2015.4296.","journal-title":"Mol Med Rep"},{"issue":"2","key":"1898_CR98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/neuonc\/nou216","volume":"17","author":"S Herzog","year":"2015","unstructured":"Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, et al. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro Oncol. 2015;17(2):223\u201342. https:\/\/doi.org\/10.1093\/neuonc\/nou216.","journal-title":"Neuro Oncol"},{"key":"1898_CR99","doi-asserted-by":"publisher","unstructured":"Peltola K, Hollmen M, Maula SM, Rainio E, Ristam\u00e4ki R, Luukkaa M, et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia. 2009;11(7):629-IN1. https:\/\/doi.org\/10.1593\/neo.81038","DOI":"10.1593\/neo.81038"},{"key":"1898_CR100","doi-asserted-by":"publisher","unstructured":"Montano N, Cenci T, Martini M, D\u2019Alessandris QG, Pelacchi F, Ricci-Vitiani L, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia. 2011;13(12):1113-IN6. https:\/\/doi.org\/10.1593\/neo.111338","DOI":"10.1593\/neo.111338"},{"issue":"9","key":"1898_CR101","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1593\/neo.10688","volume":"12","author":"KJ Hatanpaa","year":"2010","unstructured":"Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12(9):675\u201384. https:\/\/doi.org\/10.1593\/neo.10688.","journal-title":"Neoplasia"},{"issue":"12","key":"1898_CR102","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.febslet.2010.04.019","volume":"584","author":"G Pines","year":"2010","unstructured":"Pines G, K\u00f6stler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010;584(12):2699\u2013706. https:\/\/doi.org\/10.1016\/j.febslet.2010.04.019.","journal-title":"FEBS Lett"},{"key":"1898_CR103","doi-asserted-by":"publisher","unstructured":"Weirauch U, Gr\u00fcnweller A, Cuellar L, Hartmann RK, Aigner A. U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma. nucleic acid therapeutics. 2013;23(4):264\u201372. https:\/\/doi.org\/10.1089\/nat.2012.0407","DOI":"10.1089\/nat.2012.0407"},{"issue":"2","key":"1898_CR104","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbamcr.2018.10.017","volume":"1866","author":"J Remy","year":"2019","unstructured":"Remy J, Linder B, Weirauch U, Konovalova J, Marschalek R, Aigner A, et al. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. Biochimica et Biophysica Acta (BBA)-Molec Cell Res. 2019;1866(2):175\u201389. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.10.017.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molec Cell Res"},{"issue":"20","key":"1898_CR105","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.3390\/ijms222011126","volume":"22","author":"C Seifert","year":"2021","unstructured":"Seifert C, Balz E, Herzog S, Korolev A, Ga\u00dfmann S, Paland H, et al. PIM1 inhibition affects glioblastoma stem cell behavior and kills glioblastoma stem-like cells. Int J Mol Sci. 2021;22(20):11126. https:\/\/doi.org\/10.3390\/ijms222011126.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1898_CR106","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijom.2006.01.027","volume":"35","author":"WF Chiang","year":"2006","unstructured":"Chiang WF, Yen CY, Lin CN, Liaw GA, Chiu CT, Hsia YJ, et al. Up-regulation of a serine\u2013threonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2006;35(8):740\u20135. https:\/\/doi.org\/10.1016\/j.ijom.2006.01.027.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"6","key":"1898_CR107","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/ijo.30.6.1381","volume":"30","author":"UH Beier","year":"2007","unstructured":"Beier UH, Weise JB, Laudien M, Sauerwein H, G\u00f6r\u00f6gh T. Overexpression of Pim-1 in head and neck squamous cell carcinomas. Int J Oncol. 2007;30(6):1381\u20137. https:\/\/doi.org\/10.3892\/ijo.30.6.1381.","journal-title":"Int J Oncol"},{"issue":"2","key":"1898_CR108","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3892\/mmr_00000102","volume":"2","author":"S Tanaka","year":"2009","unstructured":"Tanaka S, Kitamura T, Higashino F, Hida K, Ohiro Y, Ono M, et al. Pim-1 activation of cell motility induces the malignant phenotype of tongue carcinoma. Mol Med Rep. 2009;2(2):313\u20138. https:\/\/doi.org\/10.3892\/mmr_00000102.","journal-title":"Mol Med Rep"},{"key":"1898_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-014-0114-5","volume":"33","author":"X Zhu","year":"2014","unstructured":"Zhu X, Xu JJ, Hu SS, Feng JG, Jiang LH, Hou XX, et al. Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. J Exp Clin Cancer Res. 2014;33:1\u20132. https:\/\/doi.org\/10.1186\/s13046-014-0114-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1898_CR110","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/PGP.0000000000000882","volume":"42","author":"H Takeuchi","year":"2023","unstructured":"Takeuchi H, Miyamoto T, Fuseya C, Asaka R, Ida K, Ono M, et al. PIM1 is a poor prognostic factor for and potential therapeutic target in serous carcinoma of the endometrium. Int J Gynecol Pathol. 2023;42(3):282\u201392. https:\/\/doi.org\/10.1097\/PGP.0000000000000882.","journal-title":"Int J Gynecol Pathol"},{"issue":"34","key":"1898_CR111","doi-asserted-by":"publisher","first-page":"54897","DOI":"10.18632\/oncotarget.10703","volume":"7","author":"B Shannan","year":"2016","unstructured":"Shannan B, Watters A, Chen Q, Mollin S, D\u00f6rr M, Meggers E, et al. PIM kinases as therapeutic targets against advanced melanoma. Oncotarget. 2016;7(34):54897. https:\/\/doi.org\/10.18632\/oncotarget.10703.","journal-title":"Oncotarget."},{"issue":"10","key":"1898_CR112","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/bjc.2011.426","volume":"105","author":"D Mahalingam","year":"2011","unstructured":"Mahalingam D, Espitia CM, Medina EC, Esquivel JA, Kelly KR, Bearss D, et al. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer. 2011;105(10):1563\u201373. https:\/\/doi.org\/10.1038\/bjc.2011.426.","journal-title":"Br J Cancer"},{"key":"1898_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111144","volume":"523","author":"QL Wen","year":"2021","unstructured":"Wen QL, Yi HQ, Yang K, Yin CT, Yin WJ, Xiang FY, et al. Role of oncogene PIM-1 in the development and progression of papillary thyroid carcinoma: Involvement of oxidative stress. Mol Cell Endocrinol. 2021;523: 111144. https:\/\/doi.org\/10.1016\/j.mce.2020.111144.","journal-title":"Mol Cell Endocrinol"},{"issue":"21","key":"1898_CR114","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1021\/jm900943h","volume":"52","author":"ZF Tao","year":"2009","unstructured":"Tao ZF, Hasvold LA, Leverson JD, Han EK, Guan R, Johnson EF, et al. Discovery of 3 H-benzo [4, 5] thieno [3, 2-d] pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem. 2009;52(21):6621\u201336. https:\/\/doi.org\/10.1021\/jm900943h.","journal-title":"J Med Chem"},{"issue":"6","key":"1898_CR115","doi-asserted-by":"publisher","first-page":"448","DOI":"10.18632\/oncotarget.283","volume":"2","author":"LP Forshell","year":"2011","unstructured":"Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, et al. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget. 2011;2(6):448. https:\/\/doi.org\/10.18632\/oncotarget.283.","journal-title":"Oncotarget."},{"issue":"11","key":"1898_CR116","doi-asserted-by":"publisher","first-page":"129995","DOI":"10.1016\/j.bbagen.2021.129995","volume":"1865","author":"A Rathi","year":"2021","unstructured":"Rathi A, Kumar D, Hasan GM, Haque MM, Hassan MI. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochimica et Biophysica Acta (BBA)-General Subjects. 2021;1865(11):129995.https:\/\/doi.org\/10.1016\/j.bbagen.2021.129995.","journal-title":"Biochimica et Biophysica Acta (BBA)-General Subjects"},{"issue":"11","key":"1898_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294065","volume":"18","author":"K Ingle","year":"2023","unstructured":"Ingle K, LaComb JF, Graves LM, Baines AT, Bialkowska AB. AUM302, a novel triple kinase PIM\/PI3K\/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLoS ONE. 2023;18(11): e0294065. https:\/\/doi.org\/10.1371\/journal.pone.0294065.","journal-title":"PLoS ONE"},{"issue":"14","key":"1898_CR118","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1016\/j.bmcl.2012.05.098","volume":"22","author":"LA Dakin","year":"2012","unstructured":"Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, et al. Discovery of novel benzylidene-1, 3-thiazolidine-2, 4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012;22(14):4599\u2013604. https:\/\/doi.org\/10.1016\/j.bmcl.2012.05.098.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"1898_CR119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4155\/fmc.14.145","volume":"7","author":"BT Le","year":"2015","unstructured":"Le BT, Kumarasiri M, Adams JR, Yu M, Milne R, Sykes MJ, et al. Targeting Pim kinases for cancer treatment: opportunities and challenges. Future Med Chem. 2015;7(1):35\u201353. https:\/\/doi.org\/10.4155\/fmc.14.145.","journal-title":"Future Med Chem"},{"issue":"2","key":"1898_CR120","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4143\/crt.2017.341","volume":"51","author":"M Lee","year":"2019","unstructured":"Lee M, Lee KH, Min A, Kim J, Kim S, Jang H, et al. Pan-Pim kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with Akt inhibition in gastric cancer cells. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2019;51(2):451\u201363. https:\/\/doi.org\/10.4143\/crt.2017.341.","journal-title":"Cancer Research and Treatment: Official Journal of Korean Cancer Association"},{"issue":"2","key":"1898_CR121","doi-asserted-by":"publisher","first-page":"dju407","DOI":"10.1093\/jnci\/dju407","volume":"107","author":"AN Kirschner","year":"2015","unstructured":"Kirschner AN, Wang J, Van Der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Nat Canc Inst. 2015;107(2):dju407. https:\/\/doi.org\/10.1093\/jnci\/dju407.","journal-title":"J Nat Canc Inst."},{"issue":"9","key":"1898_CR122","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1016\/j.bmcl.2012.02.099","volume":"22","author":"F Pierre","year":"2012","unstructured":"Pierre F, Regan CF, Chevrel MC, Siddiqui-Jain A, Macalino D, Streiner N, et al. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorg Med Chem Lett. 2012;22(9):3327\u201331. https:\/\/doi.org\/10.1016\/j.bmcl.2012.02.099.","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"1898_CR123","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-13-2062","volume":"20","author":"PD Garcia","year":"2014","unstructured":"Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, Ison M, Zavorotinskaya T, Dai Y, Lu J, Niu XH. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014;20(7):1834\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2062.","journal-title":"Clin Cancer Res"},{"key":"1898_CR124","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fphar.2015.00070","volume":"6","author":"HJ Chon","year":"2015","unstructured":"Chon HJ, Bae KJ, Lee Y, Kim J. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015;6:70. https:\/\/doi.org\/10.3389\/fphar.2015.00070.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1898_CR125","doi-asserted-by":"publisher","first-page":"13399","DOI":"10.1038\/s41598-017-13557-z","volume":"7","author":"J Bogusz","year":"2017","unstructured":"Bogusz J, Zrubek K, Rembacz KP, Grudnik P, Golik P, Romanowska M, Wladyka B, Dubin G. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Sci Rep. 2017;7(1):13399. https:\/\/doi.org\/10.1038\/s41598-017-13557-z.","journal-title":"Sci Rep"},{"key":"1898_CR126","doi-asserted-by":"publisher","unstructured":"Haddach M, Michaux J, Schwaebe MK, Pierre F, O\u2019Brien SE, Borsan C, Tran J, Raffaele N, Ravula S, Drygin D, Siddiqui-Jain A. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor. ACS medicinal chemistry letters. 2012 ;3(2):135\u20139. https:\/\/doi.org\/10.1021\/ml200259q","DOI":"10.1021\/ml200259q"},{"issue":"7","key":"1898_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/toxsci\/kfy035","volume":"8","author":"A Barnett","year":"2010","unstructured":"Barnett A, Ding S, Murray C, Chamberlain M, Plummer S, Evans TR, MacPherson I, Bissett D, Elcombe CR, Wolf CR. Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: human tumor xenograft efficacy and in vitro mode of action. EJC Suppl. 2010;8(7):45\u20136. https:\/\/doi.org\/10.1093\/toxsci\/kfy035.","journal-title":"EJC Suppl"},{"key":"1898_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-279","volume":"9","author":"NM Santio","year":"2010","unstructured":"Santio NM, Vahakoski RL, Rainio EM, Sandholm JA, Virtanen SS, Prudhomme M, Anizon F, Moreau P, Koskinen PJ. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer. 2010;9:1\u20133. https:\/\/doi.org\/10.1186\/1476-4598-9-279.","journal-title":"Mol Cancer"},{"issue":"20","key":"1898_CR129","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1021\/jm901018f","volume":"52","author":"R Aku\u00e9-G\u00e9du","year":"2009","unstructured":"Aku\u00e9-G\u00e9du R, Rossignol E, Azzaro S, Knapp S, Filippakopoulos P, Bullock AN, Bain J, Cohen P, Prudhomme M, Anizon F, Moreau P. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem. 2009Oct 22;52(20):6369\u201381.","journal-title":"J Med Chem"},{"issue":"14","key":"1898_CR130","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41388-020-1202-y","volume":"39","author":"SP Kennedy","year":"2020","unstructured":"Kennedy SP, O\u2019Neill M, Cunningham D, Morris PG, Toomey S, Blanco-Aparicio C, Martinez S, Pastor J, Eustace AJ, Hennessy BT. Preclinical evaluation of a novel triple-acting PIM\/PI3K\/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020;39(14):3028\u201340. https:\/\/doi.org\/10.1038\/s41388-020-1202-y.","journal-title":"Oncogene"},{"issue":"8","key":"1898_CR131","doi-asserted-by":"publisher","first-page":"e10058","DOI":"10.15252\/emmm.201810058","volume":"11","author":"S Mohlin","year":"2019","unstructured":"Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O\u2019Neill M, Pastor J, von Stedingk K. Anti-tumor effects of PIM\/PI 3K\/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mole Med. 2019;11(8):e10058. https:\/\/doi.org\/10.15252\/emmm.201810058.","journal-title":"EMBO Mole Med."},{"key":"1898_CR132","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs. 2014;32:825\u201337. https:\/\/doi.org\/10.1007\/s10637-014-0120-7.","journal-title":"Invest New Drugs"},{"issue":"15_Supplement","key":"1898_CR133","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1538-7445.AM2015-5323","volume":"75","author":"JS Small","year":"2015","unstructured":"Small JS, Holder SL. Targeting PIM1 and CDK4\/6 kinases in renal cell carcinoma. Canc Res. 2015;75(15_Supplement):5323. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-5323.","journal-title":"Canc Res."},{"key":"1898_CR134","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejmech.2018.04.056","volume":"154","author":"B Oyallon","year":"2018","unstructured":"Oyallon B, Brachet-Botineau M, Log\u00e9 C, Bonnet P, Souab M, Robert T, Ruchaud S, Bach S, Berthelot P, Gouilleux F, Viaud-Massuard MC. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors. Eur J Med Chem. 2018;154:101\u20139. https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.056.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1898_CR135","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/molecules26040867","volume":"26","author":"B Oyallon","year":"2021","unstructured":"Oyallon B, Brachet-Botineau M, Log\u00e9 C, Robert T, Bach S, Ibrahim S, Raoul W, Croix C, Berthelot P, Guillon J, Pinaud N. New quinoxaline derivatives as dual Pim-1\/2 kinase inhibitors: Design, synthesis and biological evaluation. Molecules. 2021;26(4):867. https:\/\/doi.org\/10.3390\/molecules26040867.","journal-title":"Molecules"},{"issue":"1","key":"1898_CR136","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1535-7163.MCT-06-0397","volume":"6","author":"S Holder","year":"2007","unstructured":"Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007;6(1):163\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0397.","journal-title":"Mol Cancer Ther"},{"key":"1898_CR137","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00395-009-0055-x","volume":"105","author":"M Willert","year":"2010","unstructured":"Willert M, Augstein A, Poitz DM, Schmeisser A, Strasser RH, Braun-Dullaeus RC. Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation. Basic Res Cardiol. 2010;105:267\u201377. https:\/\/doi.org\/10.1007\/s00395-009-0055-x.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"1898_CR138","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1158\/1535-7163.mct-08-1037","volume":"8","author":"Z Beharry","year":"2009","unstructured":"Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, et al. Novel benzylidene-thiazolidine-2, 4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009;8(6):1473\u201383. https:\/\/doi.org\/10.1158\/1535-7163.mct-08-1037.","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"1898_CR139","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2015-11-685032","volume":"127","author":"M Bellon","year":"2016","unstructured":"Bellon M, Lu L, Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood, The Journal of the American Society of Hematology. 2016;127(20):2439\u201350. https:\/\/doi.org\/10.1182\/blood-2015-11-685032.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"1","key":"1898_CR140","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/13543776.2014.848196","volume":"24","author":"GM Arunesh","year":"2014","unstructured":"Arunesh GM, Shanthi E, Krishna MH, Sooriya Kumar J, Viswanadhan VN. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update. Expert Opin Ther Pat. 2014;24(1):5\u201317. https:\/\/doi.org\/10.1517\/13543776.2014.848196.","journal-title":"Expert Opin Ther Pat"},{"issue":"17","key":"1898_CR141","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.3390\/ijms22179440","volume":"22","author":"CP Wu","year":"2021","unstructured":"Wu CP, Li YQ, Chi YC, Huang YH, Hung TH, Wu YS. The second-generation PIM kinase inhibitor TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Int J Mol Sci. 2021;22(17):9440. https:\/\/doi.org\/10.3390\/ijms22179440.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1898_CR142","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neo.2014.05.004","volume":"16","author":"JM Foulks","year":"2014","unstructured":"Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014;16(5):403\u201312. https:\/\/doi.org\/10.1016\/j.neo.2014.05.004.","journal-title":"Neoplasia"},{"issue":"6","key":"1898_CR143","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","volume":"123","author":"EK Keeton","year":"2014","unstructured":"Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2014;123(6):905\u201313. https:\/\/doi.org\/10.1182\/blood-2013-04-495366.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"1","key":"1898_CR144","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1021\/ml500300c","volume":"6","author":"Y Xu","year":"2015","unstructured":"Xu Y, Brenning BG, Kultgen SG, Foulks JM, Clifford A, Lai S, Chan A, Merx S, McCullar MV, Kanner SB, Ho KK. Synthesis and biological evaluation of pyrazolo [1, 5-a] pyrimidine compounds as potent and selective Pim-1 inhibitors. ACS Med Chem Lett. 2015;6(1):63\u20137. https:\/\/doi.org\/10.1021\/ml500300c.","journal-title":"ACS Med Chem Lett"},{"issue":"19","key":"1898_CR145","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","volume":"114","author":"LS Chen","year":"2009","unstructured":"Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood, The Journal of the American Society of Hematology. 2009;114(19):4150\u20137. https:\/\/doi.org\/10.1182\/blood-2009-03-212852.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"10","key":"1898_CR146","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1158\/1535-7163.MCT-09-0293","volume":"8","author":"SM Mumenthaler","year":"2009","unstructured":"Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009;8(10):2882\u201393. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0293.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1898_CR147","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4161\/cbt.24343","volume":"14","author":"D Xu","year":"2013","unstructured":"Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther. 2013;14(6):492\u2013501. https:\/\/doi.org\/10.4161\/cbt.24343.","journal-title":"Cancer Biol Ther"},{"key":"1898_CR148","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1016\/j.clml.2013.05.019","volume":"13","author":"F Cervantes-Gomez","year":"2013","unstructured":"Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013;13:S317\u201329. https:\/\/doi.org\/10.1016\/j.clml.2013.05.019.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1898_CR149","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","volume":"5","author":"S Luszczak","year":"2020","unstructured":"Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduct Target Ther. 2020Jan 31;5(1):7. https:\/\/doi.org\/10.1038\/s41392-020-0109-y.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-01898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:03:35Z","timestamp":1730469815000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-01898-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"529"}}